Senior-businesswoman-explaining-strategy-with-colleagues-in-board-room

Thought Leadership

Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends

MMIT Thought Leadership

Payers Troubled by Rise of Alternative Funding Programs

By Steve Callahan and Carly Nicholas
For the past few years, the industry has grappled with the rise of a controversial new pharmacy benefits strategy: alternative funding. Alternative funding programs (AFPs), also known as specialty carve-out programs...
0 Comments Industry Trends

Claims, Lab, and EHR Data Can Make or Break a Drug Launch

By Dinesh Kabaleeswaran
Amid a projected uptick in the prevalence of chronic diseases for an increasingly aging population, it’s more imperative than ever for patients to have access to the therapies they need to treat their health condi...
0 Comments Commercial Strategy

Exploring the Role of AI in Managed Care Organizations

By Iswarya Chandramouli and Dinesh Kabaleeswaran

Artificial Intelligence (AI) technology and ChatGPT are disrupting countless industries around the world. For healthcare, the possibilities appear promising, with organizations striving to improve patient outcomes and the overall quality of care. According to Precedence Research, AI in healthcare is expected to surpass $187.95 billion dollars by 2030, growing at a CAGR of 37% during the forecast period 2022 to 2030.

0 Comments Industry Trends

Responding to 2024’s Volatile Insurance Market

By Erin Trompeter
From the spring of 2020 to March 2023, Medicaid gained approximately 20 million new members, thanks in large part to the provision for continuous enrollment during the pandemic. Once Medicaid eligibility redetermina...
0 Comments Industry Trends

How Claims and Lab Data Helps Pharma Generate Real-World Evidence

By MMIT

In our last blog on this subject, we asked three clinical experts to explain how integrated real-world and market access data helps pharma companies go to market. In this blog, our experts weigh in on how integrated data helps pharma brands identify patients, correct payer/IDN misalignment, and make better predictions to improve patient care.

How Claims and Lab Data Helps Pharma Go to Market

By MMIT

When a manufacturer is at least a year out from a drug’s PDUFA date, the market access team begins to make informed decisions about what data is necessary for a successful launch. Many are using claims, lab, and other real-world data sets to access the right patient population at the right time to drive utilization of their therapies.

What’s Ahead for Market Access in 2024?

By Diane Watson

Last year was a period of adjustment for the U.S. pharma industry, as the combination of increased financial pressures and the Inflation Reduction Act (IRA) meant adjustments to resource allocation. While concerns about macro trends like inflation and interest rates are still top of mind for manufacturers, we expect a renewed focus on efficient pipeline performance, portfolio growth, and innovative technology.

Navigating the Variances: Payer vs. Employer Coverage for Infertility and Obesity Drugs

By Grace Casaschi

As healthcare costs continue to climb, insurers are eager to control their spend. According to WTW’s Global Medical Trends Survey, 58% of insurers anticipate higher medical trend over the next three years. How stakeholders approach cost containment varies significantly depending on their priorities and incentives.

Timing Is Everything: 4 Trends to Bolster Your HCP Marketing Strategy

By Jay Shah

In the past few years, it’s become more challenging for pharmaceutical companies to promote their products directly to healthcare providers (HCPs), and COVID only exacerbated this trend. Physicians are more selective in who they choose to meet with, and many no longer accept face-to-face meetings with pharmaceutical reps. According to 2023 research, more than 50% of physicians now meet with three or fewer pharma companies on a regular basis.

Humira Biosimilars: Pricing, Contracting and Interchangeability

By Catherine Humphries and Julia Scanlan

This has been a significant year for the Humira (adalimumab) biosimilar market. AbbVie's blockbuster drug Humira, an injectable used to treat a range of inflammatory conditions, saw the end of its 20-year, $200 billion monopoly in January. By the beginning of November, nine adalimumab biosimilars had made their market debut.

0 Comments Biosimilars